



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/531403/2020
EMA/V/C/005251

Nobivac DP Plus (*canine distemper vaccine (live, attenuated)*) and *canine parvovirus vaccine (live, recombinant)*)

An overview of Nobivac DP Plus and why it is authorised in the EU

What is Nobivac DP Plus and what is it used for?

Nobivac DP Plus is a veterinary vaccine used to protect dogs against two separate infections caused by canine distemper virus and canine parvovirus.

Nobivac DP Plus contains the active substances live attenuated (weakened) canine distemper virus (CDV) and canine parvovirus (CPV).

How is Nobivac DP Plus used?

The vaccine is given to puppies from four weeks of age as a single injection of 1 ml under the skin. It can only be obtained with a prescription.

Protection against canine distemper virus starts 7 days after vaccination, and protection against canine parvovirus infection starts 3 days after vaccination. Protection lasts for 8 weeks after vaccination.

For more information about using Nobivac DP Plus, see the package leaflet or contact your veterinarian or pharmacist.

How does Nobivac DP Plus work?

Nobivac DP Plus is a vaccine. Vaccines work by 'teaching' the immune system (the body's natural defences) how to defend itself against a disease. The canine distemper virus is alive, but it has been attenuated (weakened) so that it does not cause disease and the canine parvovirus component is a genetically modified hybrid strain. When Nobivac DP Plus is given to dogs, the animals' immune system recognises the viruses as 'foreign' and makes antibodies against them. In the future, if the animals are exposed to these infections the immune system will be able to respond more quickly. This will help protect them against distemper and parvovirus (infection caused by parvovirus).



What benefits of Nobivac DP Plus have been shown in studies?

Nobivac DP Plus was investigated in six laboratory studies and one field study, which showed that the vaccine was effective at preventing clinical signs of and death caused by CDV and CPV infection and preventing viral excretion following CDV and CPV infection. The studies also showed that immunity starts after 7 days for CDV and after 3 days for CPV and lasts for 8 weeks. One field study in 87 puppies showed that 91% of puppies had protective antibodies against CPV and 99% had protective antibodies against CDV after vaccination.

What are the risks associated with Nobivac DP Plus?

The most common side effect with Nobivac DP Plus (which may affect more than 1 in 10 animals) is a small, non-painful swelling (maximum 1 cm diameter) at the injection site observed within the first week after vaccination. The swelling will resolve completely within a few days.

For the full list of side effects and restrictions of with Nobivac DP Plus, see the package leaflet.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

In case of accidental self-injection, medical advice should be sought immediately, and the package leaflet or label shown to the doctor.

Why is Nobivac DP Plus approved?

The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Nobivac DP Plus's benefits are greater than its risks and recommended that it can be approved for use in the EU.

Other information about Nobivac DP Plus?

Nobivac DP Plus received a marketing authorisation valid throughout the EU on 9 December 2020.

Further information on Nobivac DP Plus can be found on the Agency's website:

ema.europa.eu/medicines/veterinary/EPAR/nobivac-dp-plus

This overview was last updated in 06-2021.